No Data
Express News | Bausch + Lomb : RBC Raises Target Price to $20 From $18
Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2024 financial results on Wednesday, July 31, 2024. Bausch
Express News | Bausch + Lomb : Raymond James Initiates Coverage With Outperform Rating; Price Target $19
Raymond James Initiates Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $19
Raymond James analyst Gary Nachman initiates coverage on $Bausch + Lomb Corp.(BLCO.US)$ with a buy rating, and sets the target price at $19.According to TipRanks data, the analyst has a success rate
RBC Capital on Bausch + Lomb's Miebo, Xiidra, Prescription Numbers
RBC Capital notes that total prescriptions (TRx) for Bausch + Lomb's prescription for dry eye disease (DED), Miebo, increased week over week, while Xiidra (also for dry eye) printed a year over year d
Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief
New Online Resource, KnowYourDryEye.com, Aims to Increase Awareness and Education Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today
Benjamin’s : New CEO